1 于碧莲,赵水平.对氧磷酶1与动脉粥样硬化的研究进展[J].中国动脉硬化杂志,2005,13(5):655~658. 2 李升,牛熙,冉雪琴,等.香猪对氧磷酯酶基因家族的克隆及序列分析[J].中国畜牧兽医,2012,39(6):164~168. 3 胡倩,王嘉福,冉雪琴.贵州地方猪种UCP3基因多态性与肉质性状的相关性分析[J].中国畜牧杂志,2004,44(13):1~4,45. 4 赵赞梅,王汉斌.对氧磷酶的某些研究进展[J].毒理学杂志,2005,19(1):64~66. 5 姬爱国,周正奎,张路培,等.牛PON1基因对生长和胴体性状的影响[J].畜牧兽医学报,2009,40(1):122~128. 6 梁红业,吴白燕,陈大方,等.新生儿基因CYP2E1 5'端RsaⅠ和PON2311位点多态性与早产的关系[J].遗传学报,2002,29(10):847~853. 7 Aydin S, Sahin I, Aydin S, et al. The past and present of paraoxonase enzyme: Its role in the cardiovascular system and some diseases[J]. J Med Biochem, 2012, 31: 161~173. 8 Ben-david M, Elias M, Filippi J J, et al. Catalytic versatility and backups in enzyme active sites: The case of serum paraoxonase 1[J]. J Mol Biol, 2012, 418(3~4): 181~196. 9 Eom S Y, Kim Y S, Lee C J, et al. Effects of intronic and exonic polymorphisms of paraoxonase 1 (PON1) gene on serum PON1 activity in a Korean population[J]. J Korean Med Sci, 2011, 26(6): 720~725. 10 Gupta N, Gill K D, Singh S. Paraoxonase 1 (PON1) activity, polymorphisms and coronary artery disease[M]. Croatia: Published by InTech, 2012. 11 Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes[J]. Nat Struct Mol Biol, 2004, 11(5): 412~419. 12 Hegele R A. Paraoxonase genes and disease[J]. Ann Med, 1999, 31(3): 217~224. 13 Kaman D, Ilhan N, Metin K, et al. A preliminary study of human paraoxonase and PON1 L/M55-PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease[J]. Cell Biochem Funct, 2009, 27(2): 88~92. 14 Macharia M, Hassan M S, Blackhurst D, et al. The growing importance of PON1 in cardiovascular health: A review[J]. J Cardiovasc Med, 2012, 13(7): 443~453. 15 Mackness M I, Mackness B, Durington P N, et al. Paraoxonase and coronary heart disease[J]. Curr Opin Lipidol, 1998, 9(4): 319~324. 16 Mackness B, Mackness M I, Arrol S, et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high densitylipoprotein against low density lipoprotein oxidative modification[J]. FEBS Lett, 1998, 423(1): 57~60. 17 Martinelli N, Micaglio R, Consoli L, et al. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic- syndrome-related risk of coronary artery disease[J]. Exp Diabetes Res, 2012, doi:10.1155/2012/231502. 18 Mehdi M M, Rizvi S I. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: Correlation with susceptibility of LDL oxidation[J]. Arch Med Res, 2012, 43(6): 438~443. 19 Tabak O, Geligen R, Ciceki H, et al. Circulating levels of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic syndrome[J].Minerva Med, 2012, 103(4): 323~329. 20 Xie S, Li J, Chen Y, et al. Sequence identification, chromosomal mapping and tissue specific expression of the porcine paraoxonase 1 (PON1) gene[J]. Mol Biol Rep, 2010, 37(3): 1347~1353. |